Logo for TScan Therapeutics Inc

TScan Therapeutics Investor Relations Material

Latest events

Logo for TScan Therapeutics

Q2 2024

12 Aug, 2024
Logo for TScan Therapeutics

Company Presentation 2024

18 Jun, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from TScan Therapeutics Inc

Access all reports
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell receptor-engineered T cell (TCR-T) therapies to treat cancer. The company's lead candidates, TSC-100 and TSC-101, target hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation. Additionally, TScan is advancing a pipeline of multiplexed TCR-T therapies for solid tumors, supported by its proprietary ImmunoBank, which houses a diverse collection of therapeutic TCRs. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.